London Daily

Focus on the big picture.
Tuesday, Jul 15, 2025

Shanghai and Shenzhen stock markets are shaping up as viable rivals to Hong Kong in the race for the biotech IPO crown

Shanghai and Shenzhen stock markets are shaping up as viable rivals to Hong Kong in the race for the biotech IPO crown

Sixteen pre-profit biotech firms have raised a combined US$4.5 billion in Hong Kong since April 2018, compared with two listings on Nasdaq that raised US$264 million in the same period. Last year, Shanghai’s regulators allowed drug developers that have yet to earn a revenue or profit to raise funds on the Star market, followed recently by a similar green light on the ChiNext market in Shenzhen
Shanghai and Shenzhen are shaping up as viable destinations for biotech researchers to raise capital, after they drafted or enacted new rules that match Hong Kong’s overture to pre-revenue pharmaceutical and health care start-ups, bankers said.

Last year, Shanghai’s financial regulators allowed drug developers that have yet to earn a revenue or profit to raise funds via initial public offerings (IPOs) on the Science and Technology Innovation Market (Star), followed recently by a similar green light on the ChiNext stock market in Shenzhen. The changes on the two bourses match Hong Kong’s April 2018 listing rule reform, which propelled the local stock exchange to become the world’s second-largest market for biotech IPOs after New York.

“Hong Kong is still positioned as the number one IPO destination for leading Chinese biotech companies, especially those seeking overseas listings, thanks to its mature and stable legal system and abundant international capital,” said Tang Jing, who helps Chinese biotech companies raise capital and pick IPO venues as vice-president of the health care and life science investment banking team at China Renaissance. “However, we saw a change in the dynamics last year, which is speeding up this year due to rapid policy moves.”

The changes afoot reflect the competition between the three stock exchanges – Hong Kong, Shanghai and Shenzhen – to claim the crown as the go-to destination for Chinese companies. Hong Kong, with US$4.99 trillion in capitalisation as of May 15, is the biggest stand-alone stock market of the three, based on Bloomberg data, surpassing Shanghai’s US$4.94 trillion and Shenzhen’s US$1.07 trillion.

A raft of regulatory differences divide the three markets, not least China’s capital control that constrain IPOs in Shanghai and Shenzhen to raising capital denominated in renminbi. On top of the currency limitation, China’s financial regulators typically require IPO applicants to show several years of profit, while the process of approving stock sales are often subject to capricious policy shifts that may leave companies in the queue for years.

“Yuan funds raised in mainland markets can’t be readily converted into foreign currencies, making it more difficult for companies to finance overseas projects with the proceeds,” giving Hong Kong an advantage, said Samuel Ng, a partner at the international law firm Paul Hastings, who advises listing candidates.

For companies that want to tap global investors, Hong Kong has become the preferred destination, which explains why 16 pre-profit biotech companies have listed since April 2018, raising a combined US$4.5 billion. By comparison, two pre-profit drug developers listed on Nasdaq over the same period, raising US$264 million, according to Refinitiv.

Shanghai’s overture to pre-revenue start-ups have attracted two listing since mid-2019, with US$574 million raised. They add to 13 profitable pharmaceutical companies and research teams in diagnostics, medical devices and development services on the Star market. Together the 15 firms raised US$2.3 billion in capital.

ChiNext’s proposed rules – under market consultation – would open the door for unprofitable firms to list, provided they have at least 300 million yuan in sales in the latest financial year and attain a market value of at least 5 billion yuan when listed.

“The registration-based system to be adopted by ChiNext will provide another exit option for shareholders of biotech companies in China, beyond Hong Kong, New York and Shanghai,” Tang said.

Under Star’s rules, drug developers without profit or revenue are allowed to list, if they have at least one drug candidate with promising market potential – on which phase-two clinical trials have started – and a market value of over 4 billion yuan upon listing.

In Hong Kong, the biotech listing regime let drug and medical device developers with no revenue or profit to go public if they meet requirements including a market value of at least HK$1.5 billion upon listing and at least one drug candidate having regulators’ consent to start phase two trials.

Bucking the global stock market slump, InnoCare Pharma and Akeso saw their over HK$2 billion IPOs “very significantly oversubscribed” by institutional investors, while retail investors committed funds to buy 299 and 639 times the shares available respectively.

Tang attributed the boom to a perception of the health care sector’s defensiveness, its long term growth potential in China, as well as the limited number of quality biotech firms listed in Hong Kong.

Houston Huang Guobin, JP Morgan’s head of global investment banking for China, said the China biotech IPO deals pipeline is “very strong”, especially in Hong Kong. However, he cautioned retail investors to maintain a disciplined approach.

“There will always be people, having made money on their first biotech IPO, would assume they can repeat that in the second one,” he said. “Careful company analysis should be done every time, as not every company is the same.”

To be sure, IPOs are not zero-sum games, as companies with global ambitions may choose to list in multiple markets, said Christian Hogg, CEO of the novel drugs developer Hutchison China Meditech, or Chi-Med, whose shares are traded in London and New York. Chi-Med, headquartered in Hong Kong and a unit of tycoon Li Ka-shing’s CK Hutchison, operates mainly in mainland China.

“I don’t believe it is all about who’s going to win,” Hogg said, adding that at some point a Hong Kong listing may make sense to Chi-Med. “It is about building a multi-pillar equity capital market ecosystem that can feed the necessary capital into the industry to enable new drugs to be brought to China and beyond.”
Newsletter

Related Articles

0:00
0:00
Close
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
President Trump Visits Flood-Ravaged Texas, Praises Community Strength and First Responders
From Mystery to Meltdown, Crisis Within the Trump Administration: Epstein Files Ignite A Deepening Rift at the Highest Levels of Government Reveals Chaos, Leaks, and Growing MAGA Backlash
Trump Slams Putin Over War Death Toll, Teases Major Russia Announcement
Reparations argument crushed
Rainmaker CEO Says Cloud Seeding Paused Before Deadly Texas Floods
A 92-year-old woman, who felt she doesn't belong in a nursing home, escaped the death-camp by climbing a gate nearly 8 ft tall
French Journalist Acquitted in Controversial Case Involving Brigitte Macron
Elon Musk’s xAI Targets $200 Billion Valuation in New Fundraising Round
Kraft Heinz Considers Splitting Off Grocery Division Amid Strategic Review
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
EU Proposes New Tax on Large Companies to Boost Budget
Trump Imposes 35% Tariffs on Canadian Imports Amid Trade Tensions
Junior Doctors in the UK Prepare for Five-Day Strike Over Pay Disputes
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
Bitcoin Reaches New Milestone of $116,000
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
Grok Chatbot Faces International Backlash for Antisemitic Content
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
×